Nature Communications (Nov 2021)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

  • Bin Qiu,
  • Wei Guo,
  • Fan Zhang,
  • Fang Lv,
  • Ying Ji,
  • Yue Peng,
  • Xiaoxi Chen,
  • Hua Bao,
  • Yang Xu,
  • Yang Shao,
  • Fengwei Tan,
  • Qi Xue,
  • Shugeng Gao,
  • Jie He

DOI
https://doi.org/10.1038/s41467-021-27022-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

ctDNA has been shown to identify minimal residual disease (MRD) and is thus dynamically monitored in different types of tumours. Here, the authors show that serial longitudinal ctDNA analysis can be used as a tool to detect MRD, inform the use of adjuvant therapy, and predict recurrence risk in lung cancer.